key: cord-0915106-wbh2kkey
authors: Özgen, Züleyha; Aksoy, Hasan; Akın Çakıcı, Özlem; Koku Aksu, Ayşe Esra; Erdem, Ozan; Kara Polat, Asude; Gürel, Mehmet Salih
title: COVID‐19 severity and SARS‐Cov‐2 vaccine safety in pemphigus patients
date: 2022-03-10
journal: Dermatol Ther
DOI: 10.1111/dth.15417
sha: a4e23cdfa1e6e67a8e57979ed76f4551df5406ab
doc_id: 915106
cord_uid: wbh2kkey

There are safety concerns in the treatment of pemphigus patients with immunosuppressants, particularly rituximab (RTX), in times of the COVID‐19 pandemic. In the beginning, the reports were more pessimistic. However, few reports have recently pointed to manageable courses in this patient group. Therefore, we investigated the disease characteristics and demographic features of pemphigus patients in the period of the COVID‐19 pandemic. We aimed to investigate the impact of immunosuppressants on the course of COVID‐19 in pemphigus patients. Also, we tried to find out the rate of flares due to COVID‐19 and SARS‐Cov‐2 vaccines. This multicenter study included 247 patients with pemphigus from three tertiary dermatology clinics with the specialized outpatient clinic for autoimmune blistering diseases. Patients were asked standardized questions in person or via telephone calls. Also, demographic data were collected from patients' files. Two hundred forty‐four of 247 patients took the survey between August and September 2021. The data of three patients were obtained from the National Health System. We collected the data of all pemphigus patients who visited the clinics at least once in the past 3 years. Among 51 patients having COVID‐19, 40 had a non‐serious disease, whereas 11 required hospitalization. One patient died because of COVID‐19 infection. The number of patients is limited, and data depends mainly on patients' statements. RTX treatment does not require additional safety cautions than other immunosuppressives.

Pemphigus is a group of IgG-mediated autoimmune diseases in which acantholysis causes flaccid blisters and erosions. It is often treated by systemic corticosteroid and immunosuppressive drugs that may increase the risk of infections and vascular incidents.

The novel β-coronavirus SARS-CoV-2 is the pathogenic agent responsible for COVID-19, a pandemic till March 2020. Many aspects of COVID-19 in the general population are still unclear. 1 Older age, male sex, and certain comorbidities, including diabetes, obesity, lung, heart, and kidney diseases, were determined as mortality risk factors for COVID- 19. 2 Systemic corticosteroids and immunosuppressive drugs, especially rituximab, are mainstays of pemphigus treatment. Concerns over rituximab treatment are originated from the damage on B-cells which generally takes more than 6 months to recovery. In addition, it requires intravenous administration leading to hospitalization may increase the patient's risk of contact with SARS-CoV-2. Therefore, early on in the pandemic, Mahmoudi et al. advised postponing rituximab infusions as much as possible. 3 Limited reports point out that the lately rituximab received pemphigus patients' clinical course of COVID-19 is not severe as feared. 4, 5 Also, a recent meta-analysis reported that patients with autoimmune blistering diseases (AIBDs) with more severe COVID-19 courses had a higher frequency of receiving rituximab treatment. 6 According to this data, the EADV (European Academy of Dermatology and Venereology) AIBD task force still does not recommend using rituximab as maintenance therapy to prevent relapses. 7 Immunosuppression is identified as an independent risk factor for increased mortality in COVID-19. [8] [9] [10] Although the speculations that immunosuppressive treatments may have a potential therapeutic role in the cytokine storm syndrome observed during the SARS-Cov-2 infection course, in reality, the COVID-19 pandemic brings a serious challenge for the management of patients with Pemphigus. 11, 12 Therefore, we aimed to investigate COVID-19 frequency and severity as well as the impact of treatment on COVID course in pemphigus patients. Also, disease flares induced by vaccines and COVID-19 were analyzed.

The study was conducted between August and September 2021. In this study, three tertiary dermatology clinics with specialized outpatient clinics for autoimmune blistering diseases in Istanbul/Turkey participated. The study was approved by the National Health Minister Ethic committee. Pemphigus vulgaris/foliaceus patients who visited these clinics at least once in the past 3 years were asked standardized questions as a computer-generated survey in person or via telephone calls. Also, demographic data were collected from patients' files. The pemphigus was diagnosed based on the histopathological demonstrating intraepidermal separation with detecting of IgG or/and comple- Table 1 summarizes the main demographics, characteristics, and vaccine status of SARS-Cov-2 infected or non-infected pemphigus patients. Total 51 patients were diagnosed COVID-19, and all patients stated that they were PCR-positive for the virus. Total 11 of 51 (21.57%) patients were hospitalized due to COVID-19. Only one of 11 patients transferred to the intensive care unit and then died. This patient was a 57-year-old male with diabetes mellitus type 2. He had no history of rituximab usage and was not treated by any immunosuppressive treatment for the last 2 years.

He was under treatment of 8 mg/day PO methylprednisolone. Table 2 summarizes the characteristics of SARS-Cov-2 infected and vaccinated Non-steroidal adjuvant therapies usage was higher in hospitalized (18.2%) than non-hospitalized (7.5%) COVID-19 diagnosed patients.

However, there was no statistical difference in steroid usage and dosage (Table 3) . In subgroup analysis, nine of 17 patients were treated with RTX within 12 months, and three of nine (33.3%) were hospitalized. Only one hospitalized patient was using systemic steroids other than rituximab before COVID-19, whereas the rest were not receiving additional systemic steroid or adjuvant therapy. Therefore, none of them needed to be transferred to the intensive care unit, or none of them died due to COVID-19 infection. The mean hospitalization durations were 10 ± 3.9 versus 9.25 ± 3.4 among rituximab treated and total COVID-19 diagnosed patients, respectively. The mean ages of hospitalized total and rituximab treated patients were 56.9 ± 14.4 and 51 ± 13.6, respectively. However, two patients who were recently rituximab treated and hospitalized patients were young (26 and 47 years), and they did not have comorbidities. The percentage of females in total hospitalization patients was 72.7, whereas in rituximab treated patients was 25. All discharged patients' health and general condition were well.

Our study investigated the prevalence, course of COVID-19, and flares due to infection and vaccination. Percentage of hospitalization among total, RTX non-treated and RTX treated within 12 months were 21.57%, 23.52%, and 33.3%, respectively. Longer hospitalization duration in rituximab treated patients could be due to more caution of doctors to these patients. Need to intensive care and death rate was 1/51 (1.96%) and 0/17 (0%) in total and RTX treated SARS-Cov-2 infected pemphigus patients. According to Worldometer charts, by October 4 rate of death due to in the general population of Turkey was 0.9%. 13 We can not compare death rates in the general population and pemphigus patients because they are not age-matched groups, and the number of patients is low in the study group. However, it is important that none of the patients who were treated with RTX needed intensive care or died because of COVID-19.

Our results were similar to newly released data despite more pessimistic early papers. The data of a pemphigus foliaceus patient who was infected by SARS-CoV-2 2 months after RTX infusion were reported. She required hospitalization but did not need intensive care, and she completely recovered. 2 The EADV (European Academy of Dermatology and Venereology) AIBD task force currently does not recommend the use of rituximab to prevent relapses, especially for non-vaccinated patients. 6 The EADV started an international registry for AIBD patients with confirmed COVID-19. However, they did not formally report the results yet. The results of this registry certainly will draw a road map in these hard-to-manage groups.

The patient's awareness of the risks inherent in their chronic illness may lead to very cautious patients' lifestyles, and the behaviors of patients could help our relatively relieving results.

We have insufficient data to predict the long-term effects of the SARS-CoV-2 infection, particularly for patients with profound immune system dysfunction such as pemphigus. Therefore, while larger data are needed, the risk should be calculated for each patient. It supports that there is no need to cancel following vaccine doses despite flares. The need for further treatment or treatment change was 50% and 39% in COVID-19 and vaccine groups, respectively.

Additionally, one patient other than the study group developed pemphigus vulgaris after the first administration of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Our study has some limitations. Firstly, the number of patients is not high enough. Secondly, data collection depends mainly on patients' statements. Moreover, rituximab treated patients were limited due to hesitations at the pandemic's beginning. Although our study has some limitations, each data of the pemphigus patients treated with RTX under the pandemic condition is very valuable.

In conclusion, it seems that the scenarios in RTX treatment are not scary as is expected. Also, it is important to keep in mind that SARS-CoV-2 infection and vaccines may worsen disease course and may trigger the pemphigus disease. Therefore, it is essential to measure all advantages and disadvantages of treatment choice in these hard to manage patient groups.

Insight into 2019 novel coronavirus -an updated intrim review and lessons from SARS-CoV and MERS-CoV

Case report: complete and fast recovery from severe COVID-19 in a pemphigus patient treated with rituximab. Front Immunol

Treatment of pemphigus patients in the COVID-19 era: a specific focus on rituximab

Rituximab: a safe therapeutic option during the COVID-19 pandemic?

Guidance on the use of biologic agents during COVID-19 outbreak

COVID-19 outbreak and autoimmune bullous diseases: a systematic review of published cases

Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a populationbased study in the first two months of COVID-19 outbreak in Italy

RIER investigators group. prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases

Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19

Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries

COVID-19: consider cytokine storm syndromes and immunosuppression

Patientswith bullous skin disease in a high-epidemic COVID-19 area

COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a telemedicine experience

Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic

Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: a retrospective cohort study

COVID-19 outcomes in patients with autoimmune blistering disease

The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: a population-based cohort study

Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases

The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?

COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients

The authors declared that they have no conflict of interest. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0002-9377-9548Hasan Aksoy https://orcid.org/0000-0002-5207-9633Özlem Akın Çakıcı https://orcid.org/0000-0003-3161-4139Ayşe Esra Koku Aksu https://orcid.org/0000-0002-3457-1958Ozan Erdem https://orcid.org/0000-0002-6012-0528Asude Kara Polat https://orcid.org/0000-0002-5040-6901Mehmet Salih Gürel https://orcid.org/0000-0002-7031-6516